The aim of this work was to investigate the predictive factors for bladder cancer recurrence survival (BCRS) in patients with upper-tract urothelial carcinoma (UTUC).
Methods:
We selected patients with UTUC who underwent segmental ureterectomy (Su) or nephroureterectomy (Nu) from 2004 to 2013 from the Surveillance, Epidemiology, and End Results (SEER) database. Patients with a history of intravesical therapy for bladder cancer and bladder cancer prior to the diagnosis of UTUC were excluded. We used Kaplan-Meier analysis, log-rank tests, and Cox proportional hazards model to compare overall survival, cancer-specific survival, and BCRS.
Results:
In a cohort of 1,454 patients, 169 (11.6%) had low-grade tumors and 1,285 (88.4%) had high-grade tumors; 239 (16.4%) underwent Su and 1,215 (83.6%) underwent Nu. We found that T4 grade (hazard ratio [HR] = 6.216; 95% confidence interval [CI], 3.197-12.087) and ureteral tumors (HR = 1.764; 95% CI, 1.173-2.652) were predictors of shorter BCRS, whereas Nu (HR = 0.608; 95% CI, 0.388-0.953) predicted longer BCRS. Five-year BCRS rates were low-grade tumors: 94.1%, high-grade tumors: 85.4% (p = 0.038); plus Su: 82.9%, and Nu: 87.6% (p = 0.016).
Conclusions:
Use of Su should be more selective for high-grade tumors, as it correlates with shorter BCRS. Tumors located in the ureter are associated with shorter BCRS than those located in the renal pelvis.
ChappidiMRKatesMJohnsonMH, et al. Lymph node yield and tumor location in patients with upper tract urothelial carcinoma undergoing nephroureterectomy affects survival: A U.S. population-based analysis (2004-2012). Urol Oncol. 2016;34(12):531.e15-e24.
2.
RamanJDLinYKKaagM, et al. High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy. Urol Oncol. 2014;32(1):47.e9-47.e14.
3.
AudenetFTraxerOYatesDRCussenotORouprêtM.Potential role of photodynamic techniques combined with new generation flexible ureterorenoscopes and molecular markers for the management of urothelial carcinoma of the upper urinary tract. BJU Int. 2012;109(4):608-613, discussion 613-614.
4.
RouprêtMBabjukMCompératE, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol. 2015;68(5):868-879.
5.
FangDXiongGLiX, et al. Incidence, characteristics, treatment strategies, and oncologic outcomes of synchronous bilateral upper tract urothelial carcinoma in the Chinese population. Urol Oncol. 2015;33(2):66.e1-66.e11.
6.
FangDSeisenTYangK, et al. A systematic review and meta-analysis of oncological and renal function outcomes obtained after segmental ureterectomy versus radical nephroureterectomy for upper tract urothelial carcinoma. Eur J Surg Oncol. 2016;42(11):1625-1635.
7.
SeisenTPeyronnetBDominguez-EscrigJL, et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. Eur Urol. 2016;70(6):1052-1068.
8.
SeisenTColinPRouprêtM.Risk-adapted strategy for the kidney-sparing management of upper tract tumours. Nat Rev Urol. 2015;12(3):155-166.
9.
YamashitaRWatanabeRItoI, et al. Risk factors for intravesical recurrence after nephroureterectomy in patients with upper urinary tract urothelial carcinoma. Int Urol Nephrol. 2017;49(3):425-430.
10.
KuJHChoiWSKwakCKimHH.Bladder cancer after nephroureterectomy in patients with urothelial carcinoma of the upper urinary tract. Urol Oncol. 2011;29(4):383-387.
11.
MatsuiYUtsunomiyaNIchiokaK, et al. Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Urology. 2005;65(2):279-283.
12.
TerakawaTMiyakeHMuramakiMTakenakaAHaraIFujisawaM.Risk factors for intravesical recurrence after surgical management of transitional cell carcinoma of the upper urinary tract. Urology. 2008;71(1):123-127.
13.
YamashitaSItoAMitsuzukaK, et al. Clinical implications of intravesical recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma. Int J Urol. 2016;23(5):378-384.
14.
XylinasERinkMMargulisVKarakiewiczPNovaraGShariatSF; Upper Tract Urothelial Carcinoma Collaboration (UTUCC). Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. Eur Urol. 2012;61(5):1069-1070.
15.
ZigeunerREHuttererGChromeckiTRehakPLangnerC.Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location. BJU Int. 2006;98(6):1181-1186.
16.
NovaraGDe MarcoVDalpiazO, et al. Independent predictors of metachronous bladder transitional cell carcinoma (TCC) after nephroureterectomy for TCC of the upper urinary tract. BJU Int. 2008;101(11):1368-1374.
17.
WuYPLinTTChenSH, et al. Comparison of the efficacy and feasibility of en bloc transurethral resection of bladder tumor versus conventional transurethral resection of bladder tumor: A meta-analysis. Medicine (Baltimore). 2016;95(45):e5372.
18.
JeldresCLughezzaniGSunM, et al. Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter. J Urol. 2010;183(4):1324-1329.
19.
PakRWMoskowitzEJBagleyDH.What is the cost of maintaining a kidney in upper-tract transitional-cell carcinoma? An objective analysis of cost and survival. J Endourol. 2009;23(3):341-346.
20.
BrownGAMatinSFBusbyJE, et al. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology. 2007;70(2):252-256.
21.
SudakoffGSDunnDPGuralnickMLHellmanRSEastwoodDSeeWA.Multidetector computerized tomography urography as the primary imaging modality for detecting urinary tract neoplasms in patients with asymptomatic hematuria. J Urol. 2008;179(3):862-867, discussion 867.
22.
VemanaGKimEHBhayaniSBVetterJMStropeSA.Survival Comparison Between Endoscopic and Surgical Management for Patients With Upper Tract Urothelial Cancer: A Matched Propensity Score Analysis Using Surveillance, Epidemiology and End Results-Medicare Data. Urology. 2016;95:115-120.
23.
SimhanJSmaldoneMCEglestonBL, et al. Nephron-sparing management vs radical nephroureterectomy for low- or moderate-grade, low-stage upper tract urothelial carcinoma. BJU Int. 2014;114(2):216-220.
24.
ColinPOuzzaneAPignotG, et al. French Collaborative National Database on U.U.T.-U.C. Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study. BJU Int. 2012;110(8):1134-1141.
25.
LiuYLuJHongKHuangYMaL.Independent prognostic factors for initial intravesical recurrence after laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma. Urol Oncol. 2014;32(2):146-152.
26.
HisatakiTMiyaoNMasumoriN, et al. Risk factors for the development of bladder cancer after upper tract urothelial cancer. Urology. 2000;55(5):663-667.
27.
LughezzaniGJeldresCIsbarnH, et al. Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. Eur J Cancer. 2009;45(18):3291-3297.
28.
ChenWJKuoJYChenKKLinATChangYHChangLS.Primary urothelial carcinoma of the ureter: 11-year experience in Taipei Veterans General Hospital. J Chin Med Assoc. 2005;68(11):522-530.
29.
ScosyrevEMessingJNoyesKVeaziePMessingE.Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic oncology: an overview. Urol Oncol. 2012;30(2):126-132.
